DPP-4 inhibitors take the same incretin pathway as GLP-1 agonists but approach it from the other end: instead of mimicking the gut hormone, they block the enzyme that breaks it down, so the body's own supply lasts longer. They are oral, well tolerated and weight-neutral, but their effect on blood sugar is more modest than a GLP-1 injection.
Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons